-
公开(公告)号：US11530244B2
公开(公告)日：2022-12-20
申请号：US17253864
申请日：2019-06-20
发明人： Alonso Ricardo , Thomas Joseph Tucker , Nicolas Cedric Boyer , Joseph R. Stringer , Derek M. LaPlaca , Angela Dawn Kerekes , Chengwei Wu , Sookhee Nicole Ha , Hyewon Youm , Mark W. Embrey , Elisabetta Bianchi , Danila Branca , Raffaele Ingenito , Willy Costantini , Alessia Santoprete , Roberto Costante , Immacolata Conte , Stefania Colarusso , Eric J. Gilbert , Aurash Shahripour , Yusheng Xiong
摘要： Provided herein are cyclic polypeptide compounds that can, e.g., bind specifically to human proprotein convertase subtilisin/kexin type 9 (PCSK9) and optionally also inhibit interaction between human PCSK9 and human low density lipoprotein receptor (LDLR), and pharmaceutical compositions comprising one or more of these compounds. Also provided are methods of reducing LDL cholesterol level in a subject in need thereof that include administering to the subject one or more of the cyclic polypeptide compounds or a pharmaceutical composition provided herein.
-
公开(公告)号：US20230303625A1
公开(公告)日：2023-09-28
申请号：US17935726
申请日：2022-09-27
发明人： Alonso Ricardo , Thomas Joseph Tucker , Nicolas Cedric Boyer , Joseph R. Stringer , Derek M. LaPlaca , Angela Dawn Kerekes , Chengwei Wu , Sookhee Nicole HA , Hyewon Youm , Mark W. EMBREY , Elisabetta Bianchi , Danila Branca , Raffaele Ingenito , Willy Costantini , Alessia Santoprete , Roberto Costante , Immacolata Conte , Stefania Colarusso , Eric J. GILBERT , Aurash Shahripour , Yusheng Xiong
IPC分类号： C07K7/64
摘要： Provided herein are cyclic polypeptide compounds that can, e.g., bind specifically to human proprotein convertase subtilisin/kexin type 9 (PCSK9) and optionally also inhibit interaction between human PCSK9 and human low density lipoprotein receptor (LDLR), and pharmaceutical compositions comprising one or more of these compounds. Also provided are methods of reducing LDL cholesterol level in a subject in need thereof that include administering to the subject one or more of the cyclic polypeptide compounds or a pharmaceutical composition provided herein.
-
公开(公告)号：US12012468B2
公开(公告)日：2024-06-18
申请号：US17935726
申请日：2022-09-27
发明人： Alonso Ricardo , Thomas Joseph Tucker , Nicolas Cedric Boyer , Joseph R. Stringer , Derek M. LaPlaca , Angela Dawn Kerekes , Chengwei Wu , Sookhee Nicole Ha , Hyewon Youm , Mark W. Embrey , Elisabetta Bianchi , Danila Branca , Raffaele Ingenito , Willy Costantini , Alessia Santoprete , Roberto Costante , Immacolata Conte , Stefania Colarusso , Eric J. Gilbert , Aurash Shahripour , Yusheng Xiong
摘要： Provided herein are cyclic polypeptide compounds that can, e.g., bind specifically to human proprotein convertase subtilisin/kexin type 9 (PCSK9) and optionally also inhibit interaction between human PCSK9 and human low density lipoprotein receptor (LDLR), and pharmaceutical compositions comprising one or more of these compounds. Also provided are methods of reducing LDL cholesterol level in a subject in need thereof that include administering to the subject one or more of the cyclic polypeptide compounds or a pharmaceutical composition provided herein.
-
公开(公告)号：US20230115176A1
公开(公告)日：2023-04-13
申请号：US17442246
申请日：2020-03-27
发明人： Willmen Wing-Menn Youngsaye , Bolin Geng , Michael R. Hale , Vincent P. Galullo , Jayashree G. Tikhe , Timothy Ryan Siegert , Alonso Ricardo , Derek M. LaPlaca , Douangsone D. Vadysirisack , Guo-Qing Tang , Kathleen Seyb , Michelle Denise Hoarty , Jonathan C. Blain , Joseph R. Stringer , Yongjin Gong , Claudio Sturino , Shawn Gallagher-Duval , Colin Diner , Burcin Akgun , Qing Cao , Douglas A. Treco , Vaishnavi Rajagopal , Ketki Ashok Dhamnaskar , Zhong Ma , Susan Ashwell , Jennifer Davoren , Xiaorong Liu , Camil Sayegh , Wenqing Xu , Alex Lemire , Audrey Belouin , Alexandria Jeanneret , Andrew Hildering , Barbara Bertani , Fabrizio MIcheli , Bemardo Pezzati , Alfonso Pozzan
IPC分类号： C07D519/00 , C07D239/10 , C07D403/10 , C07D403/12 , C07D403/14 , C07D471/04
摘要： The present disclosure presents compounds and compositions that interact with complement components. Some compounds inhibit complement activity. Included are small molecule compounds and compositions that function as C5 inhibitor compounds. Methods for inhibiting complement activity and methods of treating complement-related indications with the C5 inhibitor compounds and compositions are provided.
-
公开(公告)号：US11814445B2
公开(公告)日：2023-11-14
申请号：US17253774
申请日：2019-06-20
发明人： Alonso Ricardo , Nicolas Cedric Boyer , Joseph R. Stringer , Derek M. LaPlaca , Kelli Jette , Yili Sun
摘要： Provided herein are cyclic polypeptide compounds that can, e.g., bind specifically to human proprotein convertase subtilisin/kexin type 9 (PCSK9) and optionally also inhibit interaction between human PCSK9 and human low density lipoprotein receptor (LDLR), and pharmaceutical compositions comprising one or more of these compounds. Also provided are methods of reducing LDL cholesterol level in a subject in need thereof that include administering to the subject one or more of the cyclic polypeptide compounds or a pharmaceutical composition provided herein.
-
公开(公告)号：US20210284694A1
公开(公告)日：2021-09-16
申请号：US17253864
申请日：2019-06-20
发明人： Alonso Ricardo , Thomas Joseph Tucker , Nicolas Cedric Boyer , Joseph R. Stringer , Derek M. LaPlaca , Angela Dawn Kerekes , Chengwei Wu , Sookhee Nicole Ha , Hyewon Youm , Mark W. Embrey , Elisabetta Bianchi , Danila Branca , Raffaele Ingenito , Willy Costantini , Alessia Santoprete , Roberto Costante , Immacolata Conte , Stefania Colarusso , Eric J. Gilbert , Aurash Shahripour , Yusheng Xiong
IPC分类号： C07K7/64
摘要： Provided herein are cyclic polypeptide compounds that can, e.g., bind specifically to human proprotein convertase subtilisin/kexin type 9 (PCSK9) and optionally also inhibit interaction between human PCSK9 and human low density lipoprotein receptor (LDLR), and pharmaceutical compositions comprising one or more of these compounds. Also provided are methods of reducing LDL cholesterol level in a subject in need thereof that include administering to the subject one or more of the cyclic polypeptide compounds or a pharmaceutical composition provided herein.
-
公开(公告)号：US20220089640A1
公开(公告)日：2022-03-24
申请号：US17253774
申请日：2019-06-20
发明人： Alonso Ricardo , Nicolas Cedric Boyer , Joseph R. Stringer , Derek M. LaPlaca , Kelli Jette , Yili Sun
IPC分类号： C07K7/02
摘要： Provided herein are cyclic polypeptide compounds that can, e.g., bind specifically to human proprotein convertase subtilisin/kexin type 9 (PCSK9) and optionally also inhibit interaction between human PCSK9 and human low density lipoprotein receptor (LDLR), and pharmaceutical compositions comprising one or more of these compounds. Also provided are methods of reducing LDL cholesterol level in a subject in need thereof that include administering to the subject one or more of the cyclic polypeptide compounds or a pharmaceutical composition provided herein.
-
公开(公告)号：US11814444B2
公开(公告)日：2023-11-14
申请号：US17253764
申请日：2019-06-20
发明人： Alonso Ricardo , Nicolas Cedric Boyer , Joseph R. Stringer , Derek M. LaPlaca , Ketki Ashok Dhamnaskar , Zhong Ma , Jonathan C. Blain , Rohit Vyasamneni
摘要： Provided herein are cyclic polypeptide compounds that can, e.g., bind specifically to human proprotein convertase subtilisin/kexin type 9 (PCSK9) and optionally also inhibit interaction between human PCSK9 and human low density lipoprotein receptor (LDLR), and pharmaceutical compositions comprising one or more of these compounds. Also provided are methods of reducing LDL cholesterol level in a subject in need thereof that include administering to the subject one or more of the cyclic polypeptide compounds or a pharmaceutical composition provided herein.
-
公开(公告)号：US20220348610A1
公开(公告)日：2022-11-03
申请号：US17253764
申请日：2019-06-20
发明人： Alonso Ricardo , Nicolas Cedric Boyer , Joseph R. Stringer , Derek M. LaPlaca , Ketki Ashok Dhamnaskar , Zhong Ma , Jonathan C. Blain , Rohit Vyasamneni
IPC分类号： C07K7/02
摘要： Provided herein are cyclic polypeptide compounds that can, e.g., bind specifically to human proprotein convertase subtilisin/kexin type 9 (PCSK9) and optionally also inhibit interaction between human PCSK9 and human low density lipoprotein receptor (LDLR), and pharmaceutical compositions comprising one or more of these compounds. Also provided are methods of reducing LDL cholesterol level in a subject in need thereof that include administering to the subject one or more of the cyclic polypeptide compounds or a pharmaceutical composition provided herein.
-
-
-
-
-
-
-
-
搜索结果
9 条记录 (耗时 0.019 秒)
